Sign in or create an account to add this stock to your watchlist.
About Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933
Debt
Debt-to-Equity RatioN/A
Current Ratio13.91
Quick Ratio13.91
Price-To-Earnings
Trailing P/E Ratio-7.66
Forward P/E Ratio-4.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.68 million
Price / Sales352.15
Cash FlowN/A
Price / CashN/A
Book Value$6.49 per share
Price / Book2.95
Profitability
EPS (Most Recent Fiscal Year)($2.50)
Net Income$-68,520,000.00
Net MarginsN/A
Return on Equity-41.99%
Return on Assets-39.01%
Miscellaneous
Employees96
Outstanding Shares30,910,000
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics (NASDAQ:ACRS) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. The biotechnology company had revenue of $1.12 million for the quarter, compared to analyst estimates of $1 million. View Aclaris Therapeutics' Earnings History.
When is Aclaris Therapeutics' next earnings date?
What price target have analysts set for ACRS?
5 brokers have issued twelve-month target prices for Aclaris Therapeutics' shares. Their forecasts range from $36.00 to $53.00. On average, they anticipate Aclaris Therapeutics' share price to reach $46.00 in the next year. View Analyst Ratings for Aclaris Therapeutics.
What are Wall Street analysts saying about Aclaris Therapeutics stock?
Here are some recent quotes from research analysts about Aclaris Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Yesterday, Pulse Biosciences (PLSE; Not Covered) presented data from two human skin studies (dose-response study & first clinical use study) using NPS technology as potential treatment for SK. We do not think the data are meaningfully important to ACRS for a few reasons, listed below." (4/13/2018)
- 2. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (2/19/2018)
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Xencor (XNCR), Corcept Therapeutics (CORT), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK), Spectrum Pharmaceuticals (SPPI), Insmed (INSM), Akcea Therapeutics (AKCA), Puma Biotechnology (PBYI), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT) and Enanta Pharmaceuticals (ENTA).
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Dr. Neal Walker D.O., Co-Founder, Chief Exec. Officer, Pres and Director (Age 48)
- Mr. Christopher V. Powala, Co-Founder and Chief Operating Officer (Age 59)
- Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer and Sec. (Age 59)
- Dr. Stuart D. Shanler M.D., Co-Founder and Chief Scientific Officer (Age 57)
- Mr. Frank Ruffo, Co-Founder and Chief Financial Officer (Age 52)
Has Aclaris Therapeutics been receiving favorable news coverage?
Media coverage about ACRS stock has trended positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a news impact score of 0.33 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.35 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Aclaris Therapeutics' major shareholders?
Aclaris Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (8.33%),
FMR LLC
(8.35%),
FMR LLC
(8.35%), BlackRock Inc. (6.82%), Sofinnova Ventures Inc (4.98%) and Citadel Advisors LLC (2.90%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Kamil Ali-Jackson, Neal Walker, Ra Capital Management, Llc, Stephen A Tullman and Ventures Fund Vii LP Vivo. View Institutional Ownership Trends for Aclaris Therapeutics.
Which institutional investors are selling Aclaris Therapeutics stock?
ACRS stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, BlackRock Inc., Point72 Asset Management L.P., Franklin Resources Inc., Loomis Sayles & Co. L P, C WorldWide Group Holding A S, Blair William & Co. IL and Rothschild Asset Management Inc.. View Insider Buying and Selling for Aclaris Therapeutics.
Which institutional investors are buying Aclaris Therapeutics stock?
ACRS stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Citadel Advisors LLC, JPMorgan Chase & Co., Foresite Capital Management IV LLC, Summit Trail Advisors LLC, Rock Springs Capital Management LP, Highbridge Capital Management LLC and Foresite Capital Management III LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.
How do I buy shares of Aclaris Therapeutics?
Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of ACRS stock can currently be purchased for approximately $19.14.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $590.61 million and generates $1.68 million in revenue each year. The biotechnology company earns $-68,520,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Aclaris Therapeutics employs 96 workers across the globe.
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (ACRS)
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aclaris Therapeutics (NASDAQ:ACRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Aclaris Therapeutics in the last 12 months. Their average twelve-month price target is $46.00, suggesting that the stock has a possible upside of 140.33%. The high price target for ACRS is $53.00 and the low price target for ACRS is $36.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $46.00 | $46.00 | $44.50 | $41.25 |
| Price Target Upside: | 140.33% upside | 160.48% upside | 127.39% upside | 71.80% upside |
Aclaris Therapeutics (NASDAQ:ACRS) Consensus Price Target History
Aclaris Therapeutics (NASDAQ:ACRS) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Aclaris Therapeutics (NASDAQ:ACRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aclaris Therapeutics (NASDAQ ACRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.00%
Aclaris Therapeutics (NASDAQ ACRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/18/2018 | Kamil Ali-Jackson | Insider | Sell | 10,000 | $20.00 | $200,000.00 | |  |
| 5/16/2018 | Andrew Kenneth William Powell | Director | Buy | 500 | $19.12 | $9,560.00 | 500 | |
| 5/7/2018 | Frank Ruffo | CFO | Buy | 1,250 | $18.22 | $22,775.00 | 156,865 | |
| 4/6/2018 | Frank Ruffo | CFO | Buy | 1,250 | $16.59 | $20,737.50 | 155,615 | |
| 4/6/2018 | Stephen A Tullman | Director | Buy | 26,700 | $16.54 | $441,618.00 | 157,507 | |
| 4/5/2018 | Neal Walker | Insider | Buy | 10,000 | $16.75 | $167,500.00 | 897,184 | |
| 8/16/2017 | Andrew N Schiff | Director | Buy | 108,601 | $23.02 | $2,499,995.02 | | |
| 3/2/2017 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 425,000 | $30.82 | $13,098,500.00 | | |
| 1/10/2017 | Anand Mehra | Director | Sell | 750,000 | $28.25 | $21,187,500.00 | | |
| 11/18/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 907,828 | $23.03 | $20,907,278.84 | | |
| 10/26/2016 | Kamil Ali-Jackson | Insider | Sell | 3,912 | $21.83 | $85,398.96 | 79,869 | |
| 9/28/2016 | Kamil Ali-Jackson | Insider | Sell | 1,841 | $24.66 | $45,399.06 | 77,798 | |
| 9/16/2016 | Ra Capital Management, Llc | Major Shareholder | Sell | 525,550 | $24.19 | $12,713,054.50 | | |
| 8/26/2016 | Kamil Ali-Jackson | Insider | Sell | 3,738 | $20.35 | $76,068.30 | 20,289 | |
| 2/23/2016 | Ra Capital Management, Llc | Major Shareholder | Buy | 39,726 | $17.15 | $681,300.90 | | |
| 1/20/2016 | Ra Capital Management, Llc | Major Shareholder | Buy | 7,803 | $19.87 | $155,045.61 | | |
| 1/13/2016 | Ra Capital Management, Llc | Major Shareholder | Buy | 15,637 | $19.10 | $298,666.70 | | |
| 10/29/2015 | Ra Capital Management, Llc | Major Shareholder | Buy | 244,200 | $14.00 | $3,418,800.00 | | |
| 10/22/2015 | Ra Capital Management, Llc | Major Shareholder | Buy | 5,410 | $14.03 | $75,902.30 | | |
| 10/21/2015 | Ra Capital Management, Llc | Major Shareholder | Buy | 34,999 | $14.89 | $521,135.11 | | |
| 10/14/2015 | Ra Capital Management, Llc | Major Shareholder | Buy | 42,813 | $14.06 | $601,950.78 | | |
| 10/13/2015 | Albert Cha | Director | Buy | 454,545 | $11.00 | $4,999,995.00 | | |
| 10/13/2015 | Fmr Llc | Insider | Buy | 335,455 | $11.00 | $3,690,005.00 | | |
| 10/13/2015 | Sofinnova Venture Partners Vii | Major Shareholder | Buy | 409,090 | $11.00 | $4,499,990.00 | | |
| 10/8/2015 | Ra Capital Management, Llc | Major Shareholder | Buy | 2,237,130 | $10.86 | $24,295,231.80 | | |
| 10/7/2015 | Vivo Ventures Vii, Llc | Major Shareholder | Buy | 13,352 | $11.00 | $146,872.00 | | |
(Data available from 1/1/2013 forward)
Aclaris Therapeutics (NASDAQ ACRS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Aclaris Therapeutics (ACRS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 24 at 1:52 PM |
| Cantor Fitzgerald Equities Analysts Cut Earnings Estimates for Aclaris Therapeutics (ACRS)
www.americanbankingnews.com - May 24 at 9:19 AM |
| $2.76 Million in Sales Expected for Aclaris Therapeutics (ACRS) This Quarter
www.americanbankingnews.com - May 23 at 4:12 AM |
| Aclaris Therapeutics (ACRS) Insider Kamil Ali-Jackson Sells 10,000 Shares
www.americanbankingnews.com - May 21 at 7:52 PM |
| -$0.95 EPS Expected for Aclaris Therapeutics (ACRS) This Quarter
www.americanbankingnews.com - May 21 at 7:44 AM |
 | Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
finance.yahoo.com - May 16 at 9:07 AM |
| Aclaris Therapeutics (ACRS) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - May 15 at 1:21 PM |
| Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting
finance.yahoo.com - May 15 at 9:22 AM |
| Aclaris Therapeutics (ACRS) Expected to Post Q2 2018 Earnings of ($0.94) Per Share
www.americanbankingnews.com - May 14 at 2:50 AM |
 | Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 9:15 AM |
| Edited Transcript of ACRS earnings conference call or presentation 8-May-18 9:00pm GMT
finance.yahoo.com - May 9 at 4:57 PM |
| Aclaris Therapeutics (ACRS) Announces Earnings Results
www.americanbankingnews.com - May 9 at 3:34 PM |
| Aclaris: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:02 AM |
| Cantor Fitzgerald Analysts Give Aclaris Therapeutics (ACRS) a $50.00 Price Target
www.americanbankingnews.com - May 8 at 6:26 PM |
| Aclaris Therapeutics beats by $0.02, beats on revenue
seekingalpha.com - May 8 at 4:56 PM |
| Aclaris Therapeutics Inc (NASDAQ:ACRS): Immense Growth Potential?
finance.yahoo.com - May 8 at 4:56 PM |
| Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
finance.yahoo.com - May 8 at 4:56 PM |
| Insider Buying: Aclaris Therapeutics (ACRS) CFO Purchases 1,250 Shares of Stock
www.americanbankingnews.com - May 7 at 8:14 PM |
| Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)
finance.yahoo.com - May 7 at 5:04 PM |
| $1.00 Million in Sales Expected for Aclaris Therapeutics (ACRS) This Quarter
www.americanbankingnews.com - May 5 at 2:11 AM |
| -$0.99 Earnings Per Share Expected for Aclaris Therapeutics (ACRS) This Quarter
www.americanbankingnews.com - May 3 at 11:18 PM |
| Aclaris Therapeutics (ACRS) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 9:40 AM |
| Aclaris Therapeutics (ACRS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 1:36 PM |
 | Context Therapeutics Co-Founder and CEO Martin Lehr Named Ernst & Young 2018 Entrepreneur of the Year ...
www.businesswire.com - April 28 at 9:15 AM |
| Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee
finance.yahoo.com - April 24 at 5:05 PM |
| Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
finance.yahoo.com - April 24 at 5:05 PM |
| Mid-stage study underway for Aclaris' ATI-502 for inherited hair loss
seekingalpha.com - April 23 at 4:48 PM |
 | Aclaris Therapeutics (ACRS) Announces First Patient Dosed in Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
www.streetinsider.com - April 23 at 4:48 PM |
| Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
finance.yahoo.com - April 23 at 8:44 AM |
| Aclaris Therapeutics' (ACRS) Buy Rating Reiterated at Guggenheim
www.americanbankingnews.com - April 19 at 11:52 PM |
| Aclaris Therapeutics (ACRS) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - April 16 at 7:35 PM |
| Aclaris Therapeutics (ACRS) Expected to Post Earnings of -$0.99 Per Share
www.americanbankingnews.com - April 16 at 7:18 PM |
| BidaskClub Lowers Aclaris Therapeutics (ACRS) to Hold
www.americanbankingnews.com - April 14 at 8:31 AM |
| Aclaris Therapeutics (ACRS) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - April 11 at 10:42 PM |
| Insider Buying: Aclaris Therapeutics (ACRS) CFO Acquires 1,250 Shares of Stock
www.americanbankingnews.com - April 9 at 7:35 PM |
| Aclaris Therapeutics (ACRS) Director Stephen A. Tullman Buys 26,700 Shares
www.americanbankingnews.com - April 9 at 7:16 PM |
| Insider Buying: Aclaris Therapeutics (ACRS) Insider Acquires 10,000 Shares of Stock
www.americanbankingnews.com - April 9 at 10:20 AM |
| Aclaris (ACRS), Cipher to Seek Regulatory Approval and Commercialize of A-101 40% in Canada
www.streetinsider.com - April 7 at 9:20 AM |
| Cantor Fitzgerald Reiterates "$50.00" Price Target for Aclaris Therapeutics (ACRS)
www.americanbankingnews.com - April 6 at 12:11 PM |
| Aclaris Therapeutics partners with Cipher Pharmaceuticals to commercialize A-101 40% for the treatment of raised seborrheic keratoses in Canada
seekingalpha.com - April 6 at 9:11 AM |
| Aclaris Therapeutics (ACRS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 1:47 PM |
| Analysts Anticipate Aclaris Therapeutics Inc (ACRS) Will Post Quarterly Sales of $1.00 Million
www.americanbankingnews.com - April 1 at 2:12 AM |
| -$0.96 EPS Expected for Aclaris Therapeutics Inc (ACRS) This Quarter
www.americanbankingnews.com - March 30 at 11:27 PM |
| Aclaris Therapeutics (ACRS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM |
| Aclaris Therapeutics (ACRS) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 12:34 PM |
| Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - March 29 at 9:12 AM |
| Aclaris Therapeutics (ACRS) PT Lowered to $52.00
www.americanbankingnews.com - March 28 at 10:48 AM |
| BidaskClub Downgrades Aclaris Therapeutics (ACRS) to Sell
www.americanbankingnews.com - March 27 at 4:00 PM |
| Aclaris Therapeutics (ACRS) Announces ATI-450 Publication in Journal of Experimental Medicine
www.streetinsider.com - March 21 at 9:53 AM |
| Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine
finance.yahoo.com - March 20 at 9:09 AM |
Aclaris Therapeutics (NASDAQ:ACRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aclaris Therapeutics (NASDAQ:ACRS) Income Statement, Balance Sheet and Cash Flow Statement
Aclaris Therapeutics (NASDAQ ACRS) Stock Chart for Friday, May, 25, 2018
Loading chart…
